Cargando…

Mesenteric inflammatory myofibroblastic tumors

Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now con...

Descripción completa

Detalles Bibliográficos
Autor principal: Chaudhary, Poras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290004/
https://www.ncbi.nlm.nih.gov/pubmed/25608706
_version_ 1782352178939166720
author Chaudhary, Poras
author_facet Chaudhary, Poras
author_sort Chaudhary, Poras
collection PubMed
description Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now considered to be neoplastic. These tumors can occur throughout the body, most commonly in the lung, mesentery and omentum. Patients commonly present with painless abdominal mass or with intestinal obstruction. IMTs may be multicentric, have a high local recurrence rate and may metastasize in rare cases. The lesions show wide variability in their histologic features and cellularity, and marked inflammatory infiltration, predominantly of plasmatocytes and lymphocytes, and occasionally neutrophils and eosinophils. Anaplastic lymphoma kinase (ALK) rearrangements and/or ALK1 and p80 immunoreactivity are reported in 33-67% of the tumors. Owing to the rarity of these lesions, there are no specific imaging findings that distinguish IMTs from other mesenteric masses. Complete surgical resection is the treatment of choice. Local recurrence rates are high, and re-excision is the preferred therapy for local recurrences. ALK-positive tumors show good response to ALK inhibitors. Current knowledge and comprehensive review of the available literature on IMTs is herein presented.
format Online
Article
Text
id pubmed-4290004
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-42900042015-01-21 Mesenteric inflammatory myofibroblastic tumors Chaudhary, Poras Ann Gastroenterol Review Inflammatory myofibroblastic tumors (IMTs), also known as inflammatory pseudotumors and inflammatory fibrosarcomas, are uncommon mesenchymal tumors composed of myofibroblastic spindle cells admixed with lymphocytes, plasma cells and eosinophils. Once thought to be reactive, these lesions are now considered to be neoplastic. These tumors can occur throughout the body, most commonly in the lung, mesentery and omentum. Patients commonly present with painless abdominal mass or with intestinal obstruction. IMTs may be multicentric, have a high local recurrence rate and may metastasize in rare cases. The lesions show wide variability in their histologic features and cellularity, and marked inflammatory infiltration, predominantly of plasmatocytes and lymphocytes, and occasionally neutrophils and eosinophils. Anaplastic lymphoma kinase (ALK) rearrangements and/or ALK1 and p80 immunoreactivity are reported in 33-67% of the tumors. Owing to the rarity of these lesions, there are no specific imaging findings that distinguish IMTs from other mesenteric masses. Complete surgical resection is the treatment of choice. Local recurrence rates are high, and re-excision is the preferred therapy for local recurrences. ALK-positive tumors show good response to ALK inhibitors. Current knowledge and comprehensive review of the available literature on IMTs is herein presented. Hellenic Society of Gastroenterology 2015 /pmc/articles/PMC4290004/ /pubmed/25608706 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Chaudhary, Poras
Mesenteric inflammatory myofibroblastic tumors
title Mesenteric inflammatory myofibroblastic tumors
title_full Mesenteric inflammatory myofibroblastic tumors
title_fullStr Mesenteric inflammatory myofibroblastic tumors
title_full_unstemmed Mesenteric inflammatory myofibroblastic tumors
title_short Mesenteric inflammatory myofibroblastic tumors
title_sort mesenteric inflammatory myofibroblastic tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290004/
https://www.ncbi.nlm.nih.gov/pubmed/25608706
work_keys_str_mv AT chaudharyporas mesentericinflammatorymyofibroblastictumors